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Abstract: The process of metastatic dissemination begins when malignant cells start to migrate and
leave the primary mass. It is now known that neoplastic progression is associated with a combination
of genetic and epigenetic events. Cancer is a genetic disease and this pathogenic concept is the basis
for a new classification of tumours, based precisely on the presence of definite genetic lesions to
which the clones are addicted. Regarding the scatter factor receptors MET and Recepteur d’Origin
Nantais (RON), it is recognised that MET is an oncogene necessary for a narrow subset of tumours
(MET-addicted) while it works as an adjuvant metastogene for many others. This notion highlights
that the anti-MET therapy can be effective as the first line of intervention in only a few MET-addicted
cases, while it is certainly more relevant to block MET in cases of advanced neoplasia that exploit
the activation of the invasive growth program to promote dissemination in other body parts. Few
data are instead related to the role played by RON, a receptor homologous to MET. We have already
demonstrated an implication of MET and RON genes in brain metastases from lung cancer. On
this basis, the aim of this work is to recapitulate and dissect the molecular basis of metastatic brain
dissemination from lung cancer. The latter is among the big killers and frequently gives rise to brain
metastases, most often discovered at diagnosis. Molecular mechanisms leading to tumour spread to
the brain are mostly unknown and in turn these tragic cases are still lacking effective therapies. Based
on previously published data from our group, we aim to summarise and analyse the pathogenic
mechanisms leading to activation of the scatter factor receptor in brain metastatic lesions of lung
primaries, from the point of view of replacing the currently used empirical treatment with a more
targeted approach.
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1. Introduction
Lung cancer is among the big killers and is frequently associated with brain metastases, most
often discovered at the time of diagnosis. Lung carcinoma includes a series of different diseases
which can roughly be divided into two groups based on clinical and histo-pathological features:
non-small cell lung cancer (NSCLC), accounting for almost 80% of lung cancer diagnoses, and small
cell lung cancer (SCLC), responsible for the remaining 20%. In 2015, the World Health Organization
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adopted the classification recently developed by the International Association for the Study of Lung
Cancer, the American Thoracic Society, and the European Respiratory Society [1]. NSCLCs are
further subclassified as adenocarcinoma (ADC), squamous cell carcinoma (SCC), neuroendocrine
tumours, large-cell carcinoma, adeno-squamous carcinoma, salivary-gland type tumours, and other
more undifferentiated tumours. Adenocarcinoma is currently the most frequent histologic type and
accounts for almost half of all cases. For resected tumours, the novel classification introduces new
entities, namely adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) to
designate non-mucinous ADC of ≤3 cm in size, with either purely lepidic growth or predominantly
lepidic growth and ≤5 mm invasion, respectively. For invasive ADC, the new classification
introduces histological subtyping based on the predominant pattern of neoplastic growth: lepidic
(formerly non-mucinous bronchioloalveolar ADC), acinar, papillary, micropapillary, and solid. Four
variants of invasive ADC are defined: invasive mucinous (formerly mucinous bronchioloalveolar
adenocarcinoma), colloid, foetal, and enteric. On the other hand, three variants that were considered
in the previous classification have been eliminated: mucinous cystadenocarcinoma, signet ring cell,
and clear cell ADC [2]. This classification has implications for the strategic management of tissue,
particularly for small biopsies and cytology samples, in order to maximise high-quality tissue available
for molecular studies. More than 75% of all histological types are related to a habit of tobacco smoking
and the association is strongest for SCLC and SCC [3]. Growing evidence points out that lung cancers
arising in smokers and in never-smokers should be thought of as separate entities, since they exhibit
distinct epidemiological, clinical, and bio-molecular features. Second-hand smoke exposure explains
some deaths among non-smokers, but many deaths are unrelated to tobacco exposure. Occupational
and environmental exposures, as well as genetic characteristics, have been identified as risk factors for
the development of lung cancer in both smokers and never-smokers.
Patients are usually asymptomatic in the early stages of the disease. This is related to the sparse
pain–fibre innervation of the lungs and the significant respiratory reserve that both lungs provide.
The lack of symptoms is particularly true for lung cancers that originate in the periphery of the lungs.
Approximately 5–10% of lung cancer patients are asymptomatic at presentation [4]. These cancers are
often detected during evaluation for unrelated medical problems or on a chest radiograph performed
for preoperative screenings. Most symptomatic lung cancer patients present with an already advanced
disease. Tumours can metastasise via lymphatic and blood vessels. Mediastinal lymph-node invasion
is among the first expressions of tumour progression and the presence of mediastinal invasion is one
of the most crucial elements relevant in determining the optimal treatment strategy. Lung carcinomas
have some preferential sites for distant metastases, among which is the brain. Secondary cerebral
lesions are most often related to small-cell lung cancer (SCLC). In recent years, brain metastases are
increasingly seen in those ADCs carrying mutations in the epidermal growth factor receptor gene
(EGFR) and EML4/ALK rearrangements, whereas SCCs tend to locally invade the thoracic wall in
many cases. The incidence of brain metastases in patients with lung cancer is approximately 25%,
with only 5% surviving beyond the first year after diagnosis. They originate from cancer cells that
have spread through the bloodstream and are associated with a poor prognosis of 4–5 months of
median survival [5]. Due to an increase in intracranial pressure as well as the number, localisation,
and rate of growth of brain metastases, they are associated with the onset of many clinical signs and
symptoms, including headaches, sometimes with vomiting or nausea, and mental changes, such as
increasing memory problems, seizures, and dizziness. Patients with known cancer and neurological
symptoms should always undergo appropriate diagnostic tests which include either a CT scan or
magnetic resonance imaging. In some cases, a biopsy is needed to reach diagnostic confirmation. Single
or solitary brain metastases in patients with good systemic performance status should be strongly
considered for surgical resection which both confirms the diagnosis and provides definitive treatment
of the lesion. Patients with poor systemic performance status and/or multiple brain metastases are
candidates for whole brain radiotherapy (RT). Whole brain RT could be efficacious in improving
Cancers 2019, 11, 271 3 of 12
symptoms and quality of life; multiple radiosurgery is an option for oligometastatic brain disease [6–8].
Most often, steroids and symptom palliation are the only therapeutic opportunity [9].
The molecular mechanisms regulating metastatic spread to the brain are largely unknown [10,11].
Currently, no prognostic or predictive markers for the management of metastatic lung cancer exist;
no therapies are available for the advanced stage of the disease defined by brain invasion, leading
to a high mortality rate. As a result, the disease burden associated with lung cancer is among the
highest of all cancer types. Thus, it is evident that metastasis formation in lung cancer is a multifaceted
process. While many mechanisms and genes/proteins involved in the process have been identified,
a breakthrough has not been achieved yet. Growing evidence suggests that metastasization follows
from the inappropriate activation of a genetic programme termed ‘invasive growth’, a physiological
process that occurs during embryonic development and post-natal organ regeneration, driven by the
MET proto-oncogene [12]. Preliminary data from our (and other) groups suggest a role of MET-driven
invasive growth in brain metastatization from lung cancer. In this work, we recapitulate and provide a
deeper analysis of the role played by the invasive growth programme during cerebral dissemination of
lung cancer, mainly focussing on the key data that unveil MET as a potentially novel actionable target.
2. Invasive Growth and Metastatic Spread
Burgeoning evidence indicates that invasive growth is executed by stem and progenitor cells and
is usurped by cancer stem cells. The MET proto-oncogene, which is expressed in both stem and cancer
cells, is a key regulator of invasive growth. MET encodes for the receptor tyrosine kinase (TKR) for
the hepatocyte growth factor (HGF) or scatter factor. It is located on chromosome 7, band q31, and
is constituted by 21 exons separated by 20 introns codifying for a trans-membrane tyrosine kinase
receptor synthesized as a single–chain precursor which undergoes post-translational cleavage into two
disulfide-linkedα andβ subunits. The extracellular domain comprises two main regions, both involved
in ligand binding. The first is known as SEMA domain, due to its homology with semaphorins, and
includes the α chain and the N-terminal portion of the β chain. The second is the “immunoglobulin-like
domain,” containing four disulfide-linked loop structures. The intracellular domains of MET include
three functional portions: (i) the juxtamembrane sequence, including the Ser975 residue, which, upon
phosphorylation, downregulates kinase activity; (ii) the catalytic region, containing Tyr1234 and
Tyr1235 residues, which, upon receptor dimerization and transphosphorylation, upregulate kinase
activity; (iii) the carboxy–terminal sequence. The residues Tyr1234 and Tyr1235, located in the catalytic
domain, are critical for receptor activation. After that, MET elicits intramolecular phosphorylation
of the other two critical tyrosine residues (Tyr 1349 and Tyr 1356) at the C-terminal of the α-chain.
These two sites and the surrounding amino acids constitute the so-called “multifunctional docking
site”, a motif that, when activated after phosphorylation, induces a series of biological processes that
leads to invasive growth. In distinct cells and tissues, MET-driven specific activities are fulfilled by
dedicated signaling cascades, with some transducers dominating over others according to the context,
timing, and biological complexity [12] (Figure 1a). It acts as a sensor of adverse microenvironmental
conditions (e.g., hypoxia and ionizing radiation) and drives cell invasion and metastasization through
the transcriptional activation of the “invasive growth signature”, a genetic program leading to
cell scattering, invasion, protection from apoptosis, and angiogenesis [3,13]. In human cancers,
deregulated MET signaling can be achieved through: (i) genetic alterations: amplification (gastric
carcinomas, liver metastases from colon cancer, lung), point mutations (kidney, hepatocellular, gastric,
head and neck carcinomas, both in hereditary and sporadic carcinomas), establishment of autocrine
loops (glioblastoma); (ii) overexpression consequent to transcriptional upregulation (in response to
micro-environmental conditions such as hypoxia or ionizing radiation) (gastro-intestinal tract, thyroid,
prostate, mammary carcinomas) [3]. The RON (Recepteur d’Origine Nantais) receptor—also known as
the macrophage-stimulating receptor-1 (MSTR1)—belongs to the family of tyrosine kinase receptors
of which MET is the prototype and displays 25% and 63% homology with its sibling receptor MET
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in the extracellular region, and 63% within the TK domain, respectively [14]. Through mechanisms
analogous to MET, (Recepteur d’Origin Nantais) RON signaling results in invasive growth [15].
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With respect to lung cancer, MET gene amplification occurs in about 4% of lung ADCs and
1% of SCC [16,17]. Accumulating preclinical and clinical evidence suggests that MET amplification
behaves as an "oncogenic driver" and thus represents an actionable therapeutic target [18]. Notably,
the emergence of MET-amplified clones has also been documented after treatment failure with tyrosine
kinase inhibitors (TKI). Engelman et al. demonstrated the development of MET amplification in
the HCC827 NSCLC cell line after exposure to increasing concentrations of the TKI gefitinib [19].
Cells lines that developed gefitinib resistance contained amplification of the MET-containing region
7q31.1 to 7q33.3. In the assessment of tumor tissue from 18 gefitinib-resistant NSCLC patients,
22% demonstrated MET amplification. Bean et al. also studied tissue from lung ADC patients in
whom gefitinib or erlotinib resistance developed and found MET amplification in 21% of the cases.
On the other hand, only 3% of patients who had not been treated with those drugs showed MET
amplification [20]. Hence, amplification of the MET oncogene allows tumors to potentially overcome
therapeutic inhibition of growth signals. Moreover, MET amplification has been reported to be
associated with reduced progression-free survival and overall survival in EGFR-mutated cancers
treated with the novel EGFR inhibitor osimertinib [21]. Thus, in a range from 15 to 20% of EGFR
mutated cases, the selective pressure exerted by EGFR blockade through targeted therapies leads to the
emergence of MET amplified subclones. The latter results in kinase overexpression and constitutive
activation, ultimately imposing resistance to EGFR inactivation [22]. More recently, it has been reported
that mutations in the MET exon 14 splice sites that cause exon 14 skipping are oncogenic. These genetic
alterations are found in a relatively elderly population of patients with NSCLC, enriched in sarcomatoid
histologies and accounting for 8–22% of cases, with an average prevalence of about 3% of ADCs and
1% of SCCs. Few data are available about the concomitant detection of MET gene amplification
and exon 14 skipping, however, concurrent MET amplification has been reported in 15–21% of MET
exon 14 positive NSCLC, and METY1003X mutations account for around 2% of the MET exon 14
alterations in NSCL [23–25]. These tumors can respond to MET-directed targeted inhibitors (e.g.,
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rizotinib, cabozantinib, capmatinib, tepotinib, and glesatinib) [26–29]. The prognosis of patients with
MET exon 14 skipping is reported similar to that of patients with major driver mutations [26]; several
studies are already challenging the inevitable development of drug resistance [30–32].
3. MET-Driven Invasive Growth in Brain Metastases from NSCLC: A Proposed Hypothesis for a
Still Obscure Phenomenon
The understanding of the molecular mechanisms underlying tumor spread to the brain is still in
its infancy and, in turn, effective treatment for these tragic cases is yet to arrive. The concept that cancer
mutated kinases molecularly mark druggable targets has led to intensive efforts to survey the kinome
across a wide spectrum of human tumor types for mutations [33] and to the development of several
targeted inhibitors [34]. It is well known that scatter factor receptors are oncogenes necessary for a
limited subset of tumors (hence, also being called addicted), while they work as adjuvant metastogenes
for many others. This notion highlights that anti-MET and anti-RON therapy can be effective as the
first line of intervention in aforementioned addicted cases, whereas it is certainly more relevant to
block MET and RON in cases of advanced neoplasms that exploit the activation of the invasive growth
program to promote distant dissemination (Figure 2) On this basis, our work hypothesis has been
focused on the analysis of the activation status of scatter factor receptors in brain metastases from
NSCLC. We already assessed the whole MET and RON mutational profile in two relevant series of
surgical samples of lung cancer and analyzed both the primary lung cancers and the lung-cancer
derived brain lesions. The somatic origin of each mutation found was confirmed by sequencing
the matched normal DNA. Mutations were detected only in malignant tissues. Overall, we found
that [35,36]: (i) MET is mutated at a high frequency in brain metastases from NSCLCs (7.4%) compared
with primary NSCLCs (4.4%) or an unselected cancer population (1–6%, data from COSMIC database,
website at https://cancer.sanger.ac.uk/cosmic). Notably, the mortality rate after brain radiotherapy
was significantly higher in tumors carrying somatic MET mutations compared with euploid wild-type
MET lesions (p < 0.008) (Figure 1b); (ii) RON is mutated at a high frequency in brain metastases from
lung cancers (9.5%) compared with an unselected cancer population (1%, data from COSMIC database,
website at https://cancer.sanger.ac.uk/cosmic). In silico analysis suggested a damaging role of the
changes found.
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Moreover, the vast majority of MET mutations found in metastatic lesions affected the extracellular
SEMA domain of th receptor, with the E168D change being the most frequent one. As discussed
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above, the SEMA domain of MET, which is shared with semaphorins, plexins, as well as the RON
receptor, consists of a highly conserved variant form of the seven-blade β-propeller fold, defined by a
set of cysteine residues, which form four disulphide bonds to stabilize the structure [37]. While the role
of the intracellular MET tyrosine kinase domain has been fully investigated, the extracellular domain
of MET is still poorly characterized. The non-catalytic SEMA domain is necessary for dimerization in
addition to HGF binding [38] and has also been found to be involved in neoplastic invasiveness by
biochemical characterization of SEMA mutants, albeit no clear mechanistic explanation is given [39].
Indeed, in vitro studies showed that SEMA mutated cells featured an increased proliferation rate,
motile phenotype, invasion capacity, and even anchorage-independent growth capacity. Notably, this
oncogenic potential was quite unexpected, since mutations do not affect receptor phosphorylation.
Although preliminary, these study results do not disprove the initial premise, since it is
conceivable that changes affecting the SEMA domain sequence may be reflected in structural
alterations of the extracellular portion of the receptor. This could, in turn, affect the physical
interactions between metastatic cells and the surrounding microenvironment, thus facilitating their
highly invasive properties. Contrary to expectations, preliminary data pointed out that cell plasticity
characterizing SEMA-mutated clones does not rely on increased deformability and adaptation to
foreign environments. The motile behavior of SEMA-mutated cells seems to be unrelated to matrix
stiffness. This finding was quite surprising, as a high migration ability, as well as an increased elasticity
and deformability, were hypothesized to be involved in dissemination of metastatic cells to the brain.
Overall, the SEMA mutants displayed: (i) an altered Young’s module (tension/deformation ratio);
(ii) activation of interatomic interactions between cell surface and surrounding stroma when the cell
was deformed; (iii) an altered extracellular matrix (ECM)/cell stiffness balance. It is well known that
morphogenesis and metastases seem to arise from the same genetic program that instructs cells to
undergo a biological process named anoikis. Through a mechanism known as epithelial-mesenchymal
transition (EMT), cancer cells acquire a metastatic phenotype [40]. Metastatic cells reach a secondary
site via blood or lymphatic vessels; after extravasation and the arrest of tumor cells in distant organs,
the EMT process could be reverted through a mesenchymal-epithelial transition (MET); this last step
coincides with cell repolarization and terminal differentiation in a tissue pattern that usually resembles
branching tubules [41]. Cancer cells can increase their traction forces in response to increased ECM
stiffness, documented by their phenotype transition, and they must also degrade ECM. Based on our
findings, we presented the hypothesis that a shift in the biomechanics plays a crucial role, centered on
the concept that the forces of deformation push cell dissemination [42]. Our preliminary data indicated
that the plasticity exhibited by SEMA-mutated cell clones is not relying on increased deformability
and adaptation to foreign environments. Instead, mutations affecting the extracellular SEMA domain
might result in an unexpected interaction between mutated cells and the ECM, which in turn favors
cellular scattering.
This crucial point may open new avenues for research focused on a deeper understanding of
tumor progression with relevant diagnostic and therapeutic implications. Overall, the rationale of
targeting MET in NSCLC has a controversial history. MET activation is responsible for about 20% of
cases of resistance to EGFR inhibitors, and there is increasing evidence regarding the sensitivity to
anti-MET inhibitors in the absence of concurrent EGFR mutations or MET ex 14 skipping variants [4].
To the best of our knowledge, the above data are the first reports of scatter factor activation in brain
lesions from lung cancers. Limitations of the present report are related to the retrospective design of
the study and the absence of a mechanistic explanation underpinning our findings. Consequently, the
generated hypothesis is that the found MET and RON mutations might have clinical and prognostic
implications as: (i) functional markers of highly aggressive lung tumors; (ii) actionable targets for a
personalized approach in patients suffering from metastatic dissemination. Moreover, we reported
an increased frequency of MET and RON mutations in a series of brain metastases from NSCLC
and enhanced radio resistance in MET-mutated lesions [5,6]. Together, these data sustain a strong
rationale for a deeper investigation of the invasive growth activation in metastatic lung cancer and
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highlight the need for identification of novel genes and key oncogenic pathways involved in NSCLC
and SCLC progression.
4. Therapeutic MET Targeting in Brain Metastases
To successfully target brain metastatic lesions, therapeutic molecules have to be able to pass
across the blood–brain barrier (BBB), which exists between the blood microcirculation system and
the brain parenchyma. Its integrity is relevant in protecting the brain from systemic toxins, in
assuring adequate nutrient levels, as well as in maintaining local homeostasis. As a net effect, it
renders the brain an anatomical sanctuary site. It is anatomically and functionally distinct from the
blood–cerebrospinal fluid barrier and the choroid plexus [43]. Blood flow alterations and altered
vessel permeability are considered key determinants in the pathophysiology of brain injuries. Many
signaling factors are known to control BBB permeability, including growth factors, miRNAs, and matrix
metalloproteinases [44]. The availability of drugs to cross the BBB depends, among other factors, on
their size [45]: The intact BBB is impenetrable to large macromolecules, including antibody-based
proteins, although several approaches to increase drug delivery to brain tumors are currently under
investigation. Small molecules account for the vast majority of available central nervous system
drugs, primarily due to their ability to penetrate the phospholipid membrane of the BBB by passive
or carrier-mediated mechanisms [46]. However, brain metastases appear to be resistant to most
conventional systemic anticancer treatments. The seed and soil concept might take into consideration
both the intrinsic properties of tumor cells and their capacity to destroy the BBB [47]. In breast cancer
patients, brain metastatic cells expressing high levels of activated MET promote the metastatic process
via upregulation of inflammatory cytokines and vascular reprogramming [48]. Pterostilbene (PTER)
is a potential agent to treat brain metastases by targeting said MET-mediated perivascular growth
and angiogenesis.
In Section 3, we described how the occurrence of MET mutations in lung cancer cells—mainly
affecting the SEMA domain of the receptor—activates their invasive potential with a preferential
tropism to the brain. Thus, based on these preliminary results, mutated MET is emerging as a
novel actionable target for these difficult-to-treat cases. Many MET inhibitors have been developed
and/or have entered clinical evaluation in recent years. A detailed description of each molecule is
beyond the scope of this review, and we have limited our discussion to those drugs which appear
most promising to target secondary brain lesions, due to their biochemical properties and structure.
Scarce data is available on the role of monoclonal antibodies inhibiting MET in controlling brain
metastases. Onartuzumab does not improve the clinical outcome in primary brain tumors, such as
glioblastoma [49]. An in vitro and in vivo screening showed Sym015, consisting of two humanized
monoclonal antibodies directed against non-overlapping epitopes of MET, to be more effective than
emibetuzumab, a monoclonal IgG4 antibody against MET currently in clinical development, in
inhibiting MET-amplified tumors (as a mechanism to overcome resistance to EGFR-targeting agents
in advanced NSCLC) [50]. Data regarding the ABT-700 antibody show similar results [51]. The
recently developed IgG2-enhanced next generation MET monoclonal antibody KTN0073 exhibits
potent anti-tumor properties both in vitro and in vivo, not only on MET-amplified cells, but also in the
juxta-membrane exon 14 deletion mutants [52]. The phage-derived anti-MET antibody 7A2/107_A07
competes with HGF, the endogenous MET ligand, as well as the HGF fragment NK1, by binding the
IG1 domain of the receptor rather than the SEMA domain. In conclusion, no clear data are available
about the role of monoclonal antibodies in halting MET-driven brain metastatic growth. Moreover,
the “selective” occurrence of somatic mutations causes one to think that this subset of patients could
benefit from small molecule inhibitors. Among the novel small inhibitors, cabozantinib, a MET,
RET, and VEGFR2 inhibitor, has been reported to be effective in radioresistant MET-mutated brain
metastases from renal cell carcinoma [53] and to show rapid intracranial response in crizotinib-resistant
MET-exon14 positive NSCLC [54]. On the other hand, the concomitant activation of the MET receptor
and the ALK fusion gene has been reported to be associated with a rapid response to crizotinib
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in NSCLC brain metastatic lesions [55]. To date, no data are available on the potential efficacy of
the novel small inhibitor glesatinib, although it shows promise in overcoming resistance to type I
anti-MET agents [56]. The combination of osimertinib and the MET inhibitor savolitinib showed
enhanced efficacy for pre-treated patients with MET-positive, EGFR-mutant NSCLC, regardless
of prior treatment with a T790M-directed therapy, with the T790M mutation being frequently
detected in brain metastases of lung tumors (the TATTON trial, website: www.ClinicalTrials.gov,
identifier: NCT02143466). Capmatinib, an orally available highly potent and selective inhibitor of MET,
demonstrated a manageable toxicity profile in treatment–naïve patients with NSCLC and MET exon14
mutation. Preliminary data reported that capmatinib is able to pass the BBB and it is active in brain.
In in vivo models, the combination of capmatinib and the pan-EGFR inhibitor afatinib completely
suppressed tumor growth in mice orthotopically injected with cells derived from brain metastasis
from NSCLC patients [57]. All in all, the EGFR-MET crosstalk is critical for aggressive behavior of
NSCLCs and occurs through activation of MAP kinases [58] and, hence, pharmacological inhibition of
MAP kinases (such as by the MEK inhibitor selumetinib) can enhance MET signaling [59]. Altiratinib
(DCC-2701) was instead designed based on the rationale of engineering a single therapeutic agent
able to address multiple hallmarks of cancer, among which was MET. This agent exhibits properties
amenable to oral administration and exhibits substantial BBB penetration, an attribute of significance
for potential treatment of MET-positive metastatic clones [60]. More recently, the novel PLB-1001
compound showed a better BBB penetrance than other MET inhibitors, with an acceptable safety
profile and achieving partial responses in MET-mutated glioblastoma [61]. It is an orally administered
compound which acts as potent, highly selective competitor for ATP binding. This preliminary data
opened the way to further evaluation of PLB-1001’s efficacy in treating secondary brain lesions from
different primary sites. Notably, quite recent data underline that HGF/MET signaling is involved
in the immune response, mainly in modulating dendritic cell function. MET inhibition in animal
models promotes adoptive T-cell transfer and boosts check-point immunotherapy by increasing T cell
infiltration in tumors, independently of the status of MET addiction of neoplastic cells. This finding
suggests the therapeutic opportunity of co-treatment in advanced cancers [62–65]. Radiotherapy is
the most widely used therapeutic approach in brain metastases; however, in some cases resistance
to ionizing radiation is responsible for therapeutic failure. MET activation is implicated in inducing
tumor radio-resistance and the occurrence of MET mutations in brain lesions from NSCLC has been
associated with a higher mortality after RT. Hence, combining radiotherapy with MET targeting is
critical to improve the treatment outcome of those lesions. Synergistic antitumor effects are well
documented both in in vitro and in vivo models [66,67], although no data from clinical trials are
yet available.
5. Conclusions
Over the past few years, the improved knowledge of the biological, genetic, and molecular
heterogeneity of tumors, together with the development of improved pharmacological technologies,
has allowed the identification of molecular targets for novel therapeutic strategies. This fast process has
led to the overall reconsideration of the biological and genetic peculiarities that can make each tumor a
pathology of its own. The identification of patients likely to respond to specific treatments according
to the presence of relevant molecular targets (personalized medicine) needs clinical studies focused
on a constant and productive interaction among the professionals with a significant background in
the various disciplines. The process of metastatic dissemination begins when malignant cells start to
migrate and leave the primary mass. Cancer is a genetic disease and this pathogenic concept is the
basis for a new classification of tumors, based precisely on the presence of definite genetic lesions to
which the clones are addicted. Growing evidence suggests that cancer cells inappropriately execute
the MET-driven invasive growth program which is actively involved in tumor onset and progression.
The presented data sheds new light on MET, and its sibling RON, as promising candidate genes in
both onset and therapy of secondary brain metastases. Further mechanistic validation is needed to test
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the presented hypothesis. If experimentally confirmed, future therapies could take advantage of novel
MET inhibitors specifically designed to cross the BBB and could possibly enhance the radio-sensitivity
of brain lesions.
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